In the last trading session, 3,180,000,000 Zomedica Corp. (NYSE:ZOM) shares changed hands as the company’s beta touched 0.53. With the company’s per share price at $1.6 changed hands at -$0.09 or -0.05% during last session, the market valuation stood at $1.56 Billion. ZOM’s last price was a discount, traded about -81.88% off its 52-week high of $2.91. The share price had its 52-week low at $0.063, which suggests the last value was 96.06% up since then. When we look at Zomedica Corp.’s average trading volume, we note the 10-day average is 79.12 Million shares, with the 3-month average coming to 180.29 Million.
Analysts gave the Zomedica Corp. (ZOM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2. If we narrow down to specifics, the data shows that none out of 1 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended ZOM as a Hold, 1 felt it is a Buy and none rated the stock as Underweight. Zomedica Corp.’s EPS for the current quarter is expected to be $0.
Zomedica Corp. (NYSE:ZOM) trade information
Although ZOM has turned red as seen at the end of in last trading. With action -5.33%, the performance over the past five days has been red. The jump to weekly highs of $1.92 on Tuesday, Mar 23 added 16.67% to the stock’s daily price. The company’s shares are showing year-to-date upside of 5.94%, with the 5-day performance at -0.2% in the red. However, in the 30-day time frame, Zomedica Corp. (NYSE:ZOM) is -0.14% down. Looking at the short shares, we see there were 59.61 Million shares sold at short interest cover period of 0.33 days.
The consensus price target for the stock as assigned by Wall Street analysts is $1.2, meaning bulls need a downside of -25% from its current market value. According to analyst projections, ZOM’s forecast low is $1.2 with $1.2 as the target high. To hit the forecast high, the stock’s price needs a -25% upsurge from its current level, while the stock would need to tank -25% for it to hit the projected low.
Zomedica Corp. (ZOM) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.9%. The 2021 estimates are for Zomedica Corp. earnings to increase by 75.1%, but the outlook for the next 5-year period is at 0% per year.
Zomedica Corp. (NYSE:ZOM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.69% of Zomedica Corp. shares while 6.75% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 6.94%. There are 40 institutions holding the Zomedica Corp. stock share, with Vanguard Group, Inc. (The) the top institutional holder. As of Dec 30, 2020, the company held 17.9% of the shares, roughly 19.34 Million ZOM shares worth $4.46 Million.
Cambridge Investment Research Advisors Inc. holds the second largest percentage of outstanding shares, with 11.34% or 12.25 Million shares worth $2.83 Million as of Dec 30, 2020.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Among Mutual Funds, the top two as of Dec 30, 2020 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 11486155 shares estimated at $2.65 Million under it, the former controlled 10.63% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 6.22% of the shares, roughly 6.72 Million shares worth around $1.55 Million.